Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors
NCT ID: NCT02307227
Last Updated: 2014-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
46 participants
INTERVENTIONAL
2006-04-30
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Secondary Objectives:
* to determine the progression free survival (PFS) and overall survival (OS);
* to evaluate the safety of the treatment with particular attention to cardiac safety.
Inclusion Criteria:
* Histologically proven breast carcinoma evaluated for HER 2 status and immune status
* Locally advanced carcinoma (UICC stage II-III)
* Age \< 70 years
* measurable lesions
* ECOG Performance Status 0-2
* Life expectancy \> 3 months
* Adequate bone marrow and hepatic functions
* Creatinine Clearance \> 40 ml/min
* Written informed consent
* Patients must be accessible for treatment and follow up
Exclusion criteria:
* Prior chemotherapy or hormonal treatments
* Brain metastases.
* Past or current history of neoplasm other than curatively treated.
* Concurrent treatment with other experimental drugs.
* Left Ventricular Ejection Fraction (LVEF) \<50 %
* History of significant neurological or psychiatric disorders.
Treatment HER2 positive (defined as 3+ at Herceptest or FISH/CISH positive) Herceptin 4mg/kg first time, then 2 mg/kg weekly with concomitant paclitaxel 80 mg/mq weekly (one cycle corresponding to 4 weeks) for 12 weeks (3 cycles). Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 6 cycles), then surgical excision
HER2 negative:
Epirubicin 90 mg/mq and docetaxel 75 mg/mq every 3 weeks for 4 cycles. Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 8 cycles), then surgical excision.
Main Parameters of Activity:
* Complete Remission (CR): complete disappearance of all previously detectable disease for a period of at least 28 days, and no new lesions.
* Partial Remission (PR): more than 30% reduction in the longest diameter of target lesions, and no new lesions.
* Stable Disease (SD): less than 30% reduction and less than 20% increase in the longest diameter of target lesions and no new lesions.
* Progressive Disease (PD): an increase in size of more than 20% of at least one lesion of previously documented disease. Or the appearance of disease at any site.
* Progression Free Survival (PFS) will be measured from the first day of the treatment until the first observation of disease progression or death due to any cause or the last date the patient was known to be progression free and alive.
* Overall Survival (OS) will be computed as the time between the first day of treatment and the date of death or the last date the patient was known to be alive.
Main Parameters of Safety:
* Adverse events, laboratory parameters.
* All toxicity will be graded using the NCI common toxicity criteria (Appendix II). Cardiac events (CHF) will be graded according to NYHA
Study procedure:
* At Baseline:
* Complete medical history, ECOG PS, physical examination (including a neurological examination, height, weight,),
* ECG
* Left ventricular ejection fraction evaluation (LVEF, evaluated by echocardiography).
* Blood chemistry (fasting blood sugar, transaminases, serum alkaline phosphatase, total bilirubin, total protein, albumin, creatinine, PT, fìbrinogen)
* Complete blood count and differential
* Calculated Creatinine Clearance/24 h
* Chest X- ray
* Abdomen computer tomography (CT) or ultrasound
* Bone scan and X-ray (if appropriate)
* Written informed consent.
* During Treatment - Every Cycle:
* Blood chemistry
* Complete blood count and differential
* Toxicity evaluation
* Physical examination
* During Treatment - Every 12 weeks (3-4 cycles):
* Breast ultrasound
* Surgical and medical evaluation
* Left ventricular ejection fraction evaluation (LVEF) evaluated by echocardiography
* ECOG PS
* Before surgery:
* Mammography, Ultrasound and Magnetic resonance
* Long term Follow up - Every 3 months for the first 2 years, every 6 months years 3-5 then yearly
* Survival
Statistical Considerations:
The aim of this phase II clinical trial is to detect 20% improvement in the pCR (i.e., from 25% to 54%). Simon's methods will be used to calculate sample size. Accrual of 46 patients has been planned considering a 80% of power to detect a 20% difference (two-sided type I error =0.05). The Chi-square test and Fisher's exact test will be used for qualitative parameters.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Locally advanced HER2+ breast cancer pts
HER2 positive (defined as 3+ at Herceptest or FISH/CISH positive):
treatment with Trastuzumab 4mg/kg first time, then 2 mg/kg weekly with concomitant paclitaxel 80 mg/mq weekly (one cycle corresponding to 4 weeks) for 12 weeks (3 cycles). Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 6 cycles), then surgical excision
Trastuzumab
Paclitaxel
Locally advanced HER2- breast cancer pts
HER2 negative:
treatment with Epirubicin 90 mg/mq and docetaxel 75 mg/mq every 3 weeks for 4 cycles. Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 8 cycles), then surgical excision.
Epirubicin
Docetaxel
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trastuzumab
Paclitaxel
Epirubicin
Docetaxel
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Locally advanced carcinoma (UICC stage II-III)
* Age \< 70 years
* measurable lesions
* ECOG Performance Status 0-2
* Life expectancy \> 3 months
* Adequate bone marrow and hepatic functions
* Creatinine Clearance \> 40 ml/min
* Written informed consent
* Patients must be accessible for treatment and follow up.
Exclusion Criteria
* Brain metastases.
* Past or current history of neoplasm other than curatively treated.
* Concurrent treatment with other experimental drugs.
* Left Ventricular Ejection Fraction (LVEF) \<50 %
* History of significant neurological or psychiatric disorders.
18 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centro di Riferimento Oncologico - Aviano
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Riccardo Dolcetti, MD
Role: PRINCIPAL_INVESTIGATOR
Centro di Riferimento Oncologico - Aviano
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro di Riferimento Oncologico
Aviano, Pordenone, Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Muraro E, Martorelli D, Turchet E, Miolo G, Scalone S, Comaro E, Talamini R, Mastorci K, Lombardi D, Perin T, Carbone A, Veronesi A, Crivellari D, Dolcetti R. A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. Breast Cancer Res. 2011;13(6):R117. doi: 10.1186/bcr3060.
Muraro E, De Zorzi M, Miolo G, Lombardi D, Scalone S, Spazzapan S, Massarut S, Perin T, Dolcetti R, Steffan A, De Re V. KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer. Front Immunol. 2022 Jan 12;12:791958. doi: 10.3389/fimmu.2021.791958. eCollection 2021.
Muraro E, Comaro E, Talamini R, Turchet E, Miolo G, Scalone S, Militello L, Lombardi D, Spazzapan S, Perin T, Massarut S, Crivellari D, Dolcetti R, Martorelli D. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. J Transl Med. 2015 Jun 27;13:204. doi: 10.1186/s12967-015-0567-0.
Miolo G, Muraro E, Martorelli D, Lombardi D, Scalone S, Spazzapan S, Massarut S, Perin T, Viel E, Comaro E, Talamini R, Bidoli E, Turchet E, Crivellari D, Dolcetti R. Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients. BMC Cancer. 2014 Dec 15;14:954. doi: 10.1186/1471-2407-14-954.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRO-18-2006
Identifier Type: -
Identifier Source: org_study_id